evi insights · Health economics and evidence

HEOR and evidence generation, designed around HTA requirements.

Cost-effectiveness and budget impact models, systematic reviews, indirect treatment comparisons, statistics and real-world evidence for pharma, biotech and MedTech companies.

Discuss your project Our services

The problem

HTA bodies apply increasingly rigorous evidence standards.

Every extrapolation, indirect comparison and utility value is probed. Under the EU HTA Regulation the same evidence must also satisfy many member states at once.

Our view

Built with an HTA assessor's perspective.

Hasan Bari reviewed company evidence at NICE across oncology, rare disease, cell and gene therapy and medical technology. We build evidence the way assessors read it.

Questions we answer

Which model structure will the EAG accept?
Is an ITC feasible with our evidence network?
How do we extrapolate immature survival data?
Which utility source will hold up?

evi insights

Economic modelling

Models for every stage of the life cycle, built to meet HTA requirements and documented so reviewers can follow every assumption.

Cost-effectiveness and cost-utility models: state transition (Markov), partitioned survival, decision trees, microsimulation and discrete event simulation
Budget impact models, stand-alone or built into the cost-effectiveness model
Interactive budget impact and payer-facing tools for pricing negotiations, in Excel/VBA and R Shiny
Early economic models for stop-go decisions, commercial planning and evidence generation planning
Exploration of value drivers and critical sensitivities, even with limited data
Pricing models to define an economically justifiable pricing corridor
Innovative pricing scenarios: indication-specific pricing, financial and performance-based risk-sharing agreements
Cost-comparison and cost-minimisation models
Local and global model adaptations, with training for affiliates in using them
Independent model review, validation and quality control in Excel/VBA, R and Python
Interactive web-based payer tools and value calculators

evi insights

Systematic review and evidence synthesis

Reviews built to NICE, HTA and JCA standards, with synthesis methods chosen for the evidence you actually have.

Systematic literature reviews of clinical trial, real-world, economic and HRQoL evidence, following internationally recognised guidelines
SLR updates for submissions and resubmissions
Targeted, rapid and pragmatic reviews when a full SLR is not needed
Meta-analysis and meta-regression: fixed and random effects, frequentist and Bayesian
Feasibility assessments for indirect treatment comparisons
Network meta-analysis, including component NMA for combination treatments
Population-adjusted methods: MAIC, STC and multilevel network meta-regression (ML-NMR)
Bucher and anchored and unanchored comparisons, with transparent reporting of rationale, assumptions and limitations
PRISMA-compliant reporting and submission-ready evidence tables
Validated AI-assisted screening and data extraction
Living, scoping and landscaping reviews
Information specialist support: search strategy design and peer review (PRISMA-S)

evi insights

Statistical analysis

Established and novel methods, with clear reports and advice on what each choice means for HTA.

Strategic advice on the HTA implications of different analytical approaches
Survival analysis and extrapolation: parametric and non-parametric models, proportional hazards testing, piecewise and spline-based models, mixture-cure models and competing risks
Adjustment for treatment switching: IPCW, two-stage estimation and RPSFTM
Additional analyses of trial data: subgroups, risk prediction models and subsequent treatment pathways
Utility analysis: EQ-5D analysis, mapping from disease-specific instruments, country tariffs and repeated-measures models
Surrogate endpoint analysis and validation
Joint modelling of longitudinal biomarkers and time-to-event outcomes
Study design: sample size, randomisation, protocol statistics sections, data collection forms and statistical analysis plans
Statistical validation: code review, quality control and independent double programming
Statistical advice to study steering and data monitoring committees
Patient-reported outcome strategy and analysis

evi insights

Real-world evidence

The right real-world data for the question, and studies designed to answer it.

Identifying fit-for-purpose real-world data sources
Design and analysis of cohort, case-control, cross-sectional and registry studies
Comparative effectiveness, safety, uptake and adherence in routine practice
External comparator arms for single-arm trials
Treatment patterns and care pathways across countries and settings
Costs of care and resource use to populate economic models
Burden of illness, cost of illness and unmet need studies
Disease natural history models
Studies in rare disease populations
RWE generation plans and evidence gap reviews
Protocols, statistical analysis plans, data curation and linkage

evi insights

Primary and desk research

Evidence that does not exist yet, collected properly.

Desk research and landscape reviews
Structured expert elicitation for model inputs and HTA submissions
Payer, HTA advisor and KOL research
Patient and HCP surveys: design, fieldwork and analysis
Qualitative interviews and focus groups
Market and opportunity understanding studies
Payer and stakeholder validation of value messages and access strategy

evi insights

AI and digital evidence tools

Responsible AI that speeds up evidence work, with expert review built in.

AI-assisted SLR screening and extraction workflows
Mapping and evaluation of AI use cases in HTA (read our analysis)
Automated HTA and pricing intelligence tracking
Interactive evidence dashboards for client teams

evi insights

Environmental sustainability assessment

The environmental case for a technology, built with the same rigour as the economic one.

Environmental sustainability assessments of products and care pathways
Carbon footprint (CO₂e) of healthcare resource use
Life cycle assessment inputs and evidence reviews
Integrated environmental and economic modelling
Environmental evidence for value dossiers, HTA submissions and NHS procurement

Interactive

HEOR methods, interactive.

Three of the analyses behind every HTA submission. Switch survival models and watch the tail change, move price and willingness to pay on the cost-effectiveness plane, and drag the evidence network.

Illustrative data and models, for demonstration only.

How an engagement runs

From decision problem to submission-ready evidence.

01
Frame the decision problem
Population, comparators, outcomes and the evidence the committee will expect.
02
Assess the evidence
Evidence gaps and assumptions to strengthen, identified early while there is time to act.
03
Build and validate
Transparent models and analyses, with every input traced to its source.
04
Support the review
Clarification questions, technical engagement and resubmission.

Inside the HTA process

Led by a former NICE HTA Technical Lead and Analyst, who knows how committees read a submission.

Across HTA systems

NICE, SMC, AWMSG, NCPE, CDA‑AMC and the EU JCA, plus US pricing work.

Senior-led

The person who scopes your project builds the model and joins the meeting.

In health since 2015

More than a decade across clinical practice, public health, agencies and HTA.

Related insights

Our analysis on this.

All insights

8PICOs in the scope of the first published JCA

EU HTA · October 2026

JCA PICO scoping: how it works and what the first reports show

How PICO scoping works in the EU joint clinical assessment, what the first published JCA reports show, and how to plan SLRs and indirect comparisons for it.

Read the analysis

100 daysJCA dossier deadline from the first request

EU HTA · October 2026